http://bmctoday.net/retinatoday/ The latest news stories from Retina Today. en-us Sun, 26 May 2013 01:04:25 GMT Sun, 26 May 2013 01:04:25 GMT BMCToday http://bmctoday.net/retinatoday/2013/04/article.asp?f=alimera-sciences-plans-resubmission-to-fda-europoean-launch-of-iluvien pSivida Corp. announced that its licensee Alimera Sciences, Inc., intends to resubmit its New Drug Application (NDA) for Iluvien (fluocinolone acetonide) to the US Food and Drug Administration (FDA), according to a company news release. The resubmission will reportedly use data from the company’s phase 3 FAME stud... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/04/article.asp?f=alimera-sciences-plans-resubmission-to-fda-europoean-launch-of-iluvien http://bmctoday.net/retinatoday/2013/04/article.asp?f=adults-with-self-reported-visual-function-loss-more-likely-to-be-depressed Adults with self-reported visual function loss were almost twice as likely to be depressed as other adults, according to a study in JAMA Ophthalmology.sup1/sup Xinzhi Zhang, MD, PhD, of the National Institutes of Health, Maryland, and colleagues conducted a study of 10,480 individuals aged 20 years or older. Depressi... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/04/article.asp?f=adults-with-self-reported-visual-function-loss-more-likely-to-be-depressed http://bmctoday.net/retinatoday/2013/04/article.asp?f=quantel-medical-receives-fda-clearance-for-vitra-multispot-laser Quantel Medical has received FDA 510(k) market clearance of the Vitra Multispot laser, according to a company news release. The Vitra Multispot combines advanced pattern scanning and solid-state green laser technologies in a compact, portable platform. This design reportedly provides a cost-effective solution to oph... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/04/article.asp?f=quantel-medical-receives-fda-clearance-for-vitra-multispot-laser http://bmctoday.net/retinatoday/2013/04/article.asp?f=ocular-complications-after-bone-marrow-transplant-may-be-common-in-pediatric-patients Ocular complications in pediatric patients who undergo hematopoietic stem cell transplantation (HSCT) may be common, according to a study published in JAMA Ophthalmology.sup1/sup Viera Kalinina Ayuso, MD, of the University Medical Center Utrecht, the Netherlands, examined the development of eye complications among 4... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/04/article.asp?f=ocular-complications-after-bone-marrow-transplant-may-be-common-in-pediatric-patients http://bmctoday.net/retinatoday/2013/04/article.asp?f=optos-oct-slo-system-receives-fda-clearance-for-microperimetry Optos PLC has received 510(k) clearance from the US Food and Drug Administration (FDA) for microperimetry as part of the Optos OCT SLO system, according to a company news release. Microperimetry assesses retinal sensitivity, providing a precise correlation between structural pathology and corresponding visual functiona... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/04/article.asp?f=optos-oct-slo-system-receives-fda-clearance-for-microperimetry http://bmctoday.net/retinatoday/2013/04/article.asp?f=the-robert-machemer-foundation-awards-first-vitreoretinal-scholarship Shunsuke Kubota, MD, PhD, has been awarded the inaugural Robert Machemer Foundation Vitreoretinal Scholarship, according to a news release. Dr. Kubota, a vitreoretinal research fellow at Washington St. Louis, was selected through a competitive application process from a group of international scholars at institution... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/04/article.asp?f=the-robert-machemer-foundation-awards-first-vitreoretinal-scholarship http://bmctoday.net/retinatoday/2013/04/article.asp?f=light-exposure-during-pregnancy-key-to-normal-eye-development New research published in Nature concluded that the eye needs light to develop normally during pregnancy.sup1/sup According to a news release from the University of California, San Francisco (UCSF), scientists reported that the unexpected finding offers a new basic understanding of fetal eye development and ocular di... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/04/article.asp?f=light-exposure-during-pregnancy-key-to-normal-eye-development http://bmctoday.net/retinatoday/2013/04/article.asp?f=shire-acquires-premacure-ab Shire plc has acquired Premacure AB of Uppsala, Sweden, a privately held biotechnology company developing a protein replacement therapy, currently in phase 2 development, for the prevention of retinopathy of prematurity (ROP), according to a news release. Shire will reportedly purchase Premacure for an upfront payme... Tue, 2 Apr 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/04/article.asp?f=shire-acquires-premacure-ab http://bmctoday.net/retinatoday/2013/03/article.asp?f=argus-ii-retinal-prosthesis-system-receives-fda-approval The Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc.) has received approval from the US Food and Drug Administration (FDA) for the treatment of late-stage retinitis pigmentosa (RP), according to a company news release. The Argus II is intended to provide electrical stimulation of the retina to... Sat, 2 Mar 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/03/article.asp?f=argus-ii-retinal-prosthesis-system-receives-fda-approval http://bmctoday.net/retinatoday/2013/03/article.asp?f=retina-implant-ag-announces-positive-results-from-second-human-clinical-trial Functional vision was restored in the majority of 9 patients with RP who were implanted with Retina Implant AG’s subretinal microchip. These results, from part of the company’s second human clinical trial, were published in Proceedings of the Royal Society B1 and reported in a news release. The study was led by ... Sat, 2 Mar 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/03/article.asp?f=retina-implant-ag-announces-positive-results-from-second-human-clinical-trial http://bmctoday.net/retinatoday/2013/03/article.asp?f=ranibizumab-saline-had-similar-effect-on-vitrectomy-rates-in-eyes-with-vitreous-hemorrhage-in-pdr There was no clinically important difference between ranibizumab (Lucentis, Genentech) and saline on the rate of vitrectomy in patients with vitreous hemorrhage from proliferative diabetic retinopathy (PDR), according to a study published in the Archives of Ophthalmology.sup1/sup The Diabetic Retinopathy Clinical Re... Sat, 2 Mar 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/03/article.asp?f=ranibizumab-saline-had-similar-effect-on-vitrectomy-rates-in-eyes-with-vitreous-hemorrhage-in-pdr http://bmctoday.net/retinatoday/2013/03/article.asp?f=national-marfan-foundation-announces-early-investigator-grant-program The National Marfan Foundation (NMF) announced a new grant program for early investigators studying Marfan syndrome and related disorders, according to a news release. The NMF is accepting applications for 2-year grants in basic or clinical research and will award a total of 3 grants for $37 500 per year. The founda... Sat, 2 Mar 2013 04:00:00 GMT http://bmctoday.net/retinatoday/2013/03/article.asp?f=national-marfan-foundation-announces-early-investigator-grant-program